RNA-targeting small molecules are rapidly emerging as a powerful therapeutic reality. From modulating splicing to directly binding RNAs, these molecules offer a revolutionary approach to treating previously undruggable diseases across neurodegenerative, cancer and rare disorders. In 2025 alone, the field has seen major collaborations, including Wayfinder Biosciences with Daiichi Sankyo, Ono Pharmaceutical with Reborna Biosciences, and xFOREST with Astellas Pharma—signaling growing momentum and industry confidence.
Join 25+ world-class speakers from leaders like PTC Therapeutics, ReviR Therapeutics, Remix Therapeutics, Rgenta Therapeutics, Arrakis Therapeutics and more this December to gain the connections, tools and scientific firepower needed to bring your RNA-targeted therapeutics to clinic and beyond.
Step into the future of RNA-targeted drugs at the 8th RNA-Targeted Drug Discovery & Development Summit. With 75% new speakers from 2024 and 50% of the speakers sharing new data, this summit is set to offer the latest data and fresh insights on small molecules targeting RNA.
This year, join 80+ experts in RNA biology, drug discovery, medicinal chemistry, and structural biology to gain the latest data on visualizing dynamic RNA structures, identifying functional binders, improving selectivity, enhancing delivery stability and achieving oral bioavailability.
Whether you’re focused on RNA splice modulators, covalent binders, proximity inducing drugs, or direct RNA binders this event will give you the tools and insights to fast track the discovery of functional binders and accelerate your pipeline of RNA-targeted small molecules to the clinic.
Connect with your global community at the world’s only meeting for RNA-targeted drug experts.
To know more visit: https://ter.li/rcvdor